46. Malignant rheumatoid arthritis Clinical trials / Disease details

Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00805467 (ClinicalTrials.gov)	August 2008	5/12/2008	Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies	An Open-Label, Multicenter Extension Study to Evaluate the Safety of R935788 in Patients With Rheumatoid Arthritis Who Have Completed the Treatment Phase of a Rigel-Sponsored R935788 Study	Rheumatoid Arthritis	Drug: Fostamatinib Disodium (R935788)	AstraZeneca	NULL	Terminated	18 Years	N/A	All	624	Phase 2	United States;Belgium;Bulgaria;Colombia;France;Germany;Italy;Mexico;Peru;Poland;Romania
2	NCT00665626 (ClinicalTrials.gov)	May 2008	22/4/2008	Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)	A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients With Rheumatoid Arthritis Who Have Failed at Least One Biologic	Rheumatoid Arthritis	Drug: Fostamatinib disodium (R935788);Drug: Placebo	Rigel Pharmaceuticals	NULL	Completed	18 Years	N/A	All	219	Phase 2	United States;Belgium;Colombia;France;Germany;Italy;Peru;Brazil
3	NCT00665925 (ClinicalTrials.gov)	May 2008	22/4/2008	Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis	A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of Two Doses of R935788 in Rheumatoid Arthritis Patients Failing to Respond to Methotrexate	Rheumatoid Arthritis	Drug: Fostamatinib disodium (R935788);Drug: Placebo	Rigel Pharmaceuticals	NULL	Completed	18 Years	N/A	All	457	Phase 2	United States;Bulgaria;Colombia;Mexico;Poland;Romania;Israel